More on PRME
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.21 |
|
|||
| Open | $3.56 | ||||
| 52 Wk High | $21.72 | ||||
| 52 Wk Low | $18.36 | ||||
| Day High | $3.72 | ||||
| Day Low | $3.26 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 7,474,923 | ||||
- Prime Medicine (PRME) Reiterated at Market Outperform by Citizens
- Prime Medicine doses first patient in Wilson disease gene editing trial
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
- Prime Drink Group Announces Filing of Annual and Interim Financial Statements and Anticipated CTO Revocation
- Prime Medicine (PRME) Reiterated at Market Outperform by Citizens - Still a Leader in Prime Editing
- Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as PM647 Application Cleared
- Prime Drink Group Provides Bi-Weekly MCTO Status Report
- Prime Medicine stock surges on FDA IND clearance
- FDA clears Prime Medicine's IND for AATD gene editing therapy
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Entities mentioned with PRME
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- IPO | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- Show More...
